TTO Flanders is a joint initiative of the five Flemish universities: Ghent University, University of Antwerp, KU Leuven, Vrije Universiteit Brussel and Hasselt University. The technology transfer offices (TTOs) of these universities are responsible for the transfer of knowledge and technology from universities and associated university colleges to private and public partners. Is your company interested in collaborating with academic research groups? Then TTO Flanders offers just what you need.
NEW IN 2019!
TTO Flanders is offering us a whole new knowledge for growth experience with an elaborate ACADEMIC SHOWCASE.
Researches from 5 universities will present their research projects.
You can find the researchers at the TTO booth (115) in the grand hall, next to the abstract posters, during all coffee & lunch breaks.
You can find more info on these projects below.
1. BruBotics - Brussels Human Robotics Research Center (dr. Pierre Cherelle, VUB)
BruBotics is a joint initiative of 8 research groups of the Vrije Universiteit Brussel. Together they strive to take the next step in Human Robotics by breaking boundaries. By combining expertise in engineering, life, computer and social sciences on the topic of Human Centered Robotics, BruBotics enables cross-boundary and cross-industry innovation. At Knowledge for Growth BruBotics will showcase its bionic prostheses as an example of how human robotics can improve the quality of life of people.
2. IVDT - In Vitro Toxicology & Dermato-cosmetology : Skin-derived hepatic cells to predict drug safety and combat liver diseases (dr. Ruani Fernando / dr. Karolien Buyl, VUB)
The global incidence of non-alcoholic fatty liver disease (NAFLD), which can progress to non-alcoholic steatohepatitis (NASH), is rapidly increasing, particularly in conjunction with the rising global prevalence of metabolic and obesity related syndromes. VUB’s liver relevant cell model represents a sensitive in vitro model for both drug-induced liver disease (DILI) prediction and anti-NASH/NAFLD drug discovery. The cell technology performs favorably against gold-standard hepatic cell models and is being optimized for high throughput screening (HTS) compatibility.
3. IB2 - Interuniversity Institute of Bioinformatics in Brussels : MutaFrame, unraveling the Human Proteome (dr. Ibrahim Tanyalcin / dr. Geoffrey Aerts, VUB)
At MutaFrame, we strive to understand how mutations impact Human Proteome and help doctors and patients to make best use of state of the art bionformatics tools to pinpoint disorder mechanism of action. We heavily rely on data visualization to clearly narrate what are the predictive leads and why they are important. We think what we are working on is an integral step to switch digital omics from bench to bedside and personalized medicine.
4. NarcoReader - Electrochemical sensors for drug detection (Prof. Dr. Karolien De Wael – UAntwerpen)
Within the UAntwerpen AXES research group, a new method was developed to achieve a fast and accurate detection of cocaine at low cost, using an electrochemical sensor. By using this method, the limitations and restrictions of existing tests can be tackled (such as sensitivity, false positives/negatives, and environmental influences). The device is being developed as a user-friendly and wearable device that can be used by authorities without scientific knowledge or training. Currently, the sensor technology is being optimized to achieve multi-drug detection.
5. Anicells – State-of-the-art manufacturing site for cell-based therapeutic products (Prof. Dr. Nathalie Cools, UAntwerpen)
Anicells is an initiative launched by the University of Antwerp and the Antwerp University Hospital based on expertise in clinical development and manufacturing of cell therapy products. Anicells facilitates and guides the go-to-patient strategy of cell therapy developers by offering regulatory support, development-on-demand, and GMP-compliant manufacturing of cell-based investigational medicinal products.
6. EGAMI – A multi-disciplinary biomedical imaging platform for pre-clinical and clinical research (Dr. Wouter Van Putte, UAntwerpen)
The EGAMI imaging consortium integrates all pre-clinical and clinical imaging units at the university of Antwerp. Developping novel imaging processing algorithms is hereby a central activity of the different research units. During this session three different proprietary software modules will be presented for (i) awake imaging for µPET, (ii) superresolution MRI and (iii) data analysis of microscopy data.
7. LumiPoreTM platform (Toon Brans / Stephan Stremersch / Kevin Braeckmans, UGent)
The new LumiPoreTM platform is a Ghent University proprietary benchtop device for state-of-the-art cell transfections. This technology combines laser light and nanotechnology to deliver macromolecular cargo’s such as oligonucleotides, antibodies and QDots directly into the cellular cytosol. Cell transfections can be performed in high-throughput mode, but can also be spatiotemporally controlled down to single cell resolution. In addition, as transmission and fluorescent microscopy imaging are integrated into the system, specific cell subpopulations can be selectively transfected based on morphological or fluorescent features. During the demo, the device will be showcased as well as what it can mean for life science researchers and cell therapy producers.
8. Nanodelivery expertise (An Van Den Bulcke / Dominic De Groote / Cristina Pintucci / Pieter Rondou / Eva De Smedt, UGent)
Ghent university institutions have world-class expertise when it comes to advanced delivery of more complex molecules to cells or biological systems. The most effective drug may result underperforming or even harmful if distributed with an inappropriate delivery system, and may never reach the clinic. Delivery is thus key to ensure that the full potential of an API is properly unfolded.
Ghent university has a particular expertise in delivering oligonucleotides and macromolecules. We offer expertise and technologies in lipid nanoparticle engineering, adjuvated particle systems, design and synthesis of (polymeric) delivering systems, controlled released, novel hydrogels carriers and surface functionalization. Our toolbox includes in vitro and in vivo models for brain, lung, ocular and intraperitoneal drug delivery, intracellular delivery and delivery approaches for immune-oncology. Our expertise reaches beyond the technology to explore and understand the nanoparticle behavior and correlate such understanding with particle functionalization, synthesis, in-vitro and in-vivo mechanism of action.
Ghent university’s expertise in nanoparticle delivery generates integrated systems for advanced application of novel drugs through tailor made solutions and materials. Our expertise reaches beyond the technology: synergic collaborations between different Ghent university groups and consortia ensure cutting edge delivery expertise, substantiated by technical and clinical validation potential.
9. OhmX.Bio unravelling genome-wide maps of translated mRNA (Karine Clauwaert / Gerben Menschaert / Hendrik Van de Voorde, UGent)
OhmX.Bio provides a complete R&D platform to help customers resolve their biological questions through cutting-edge technologies in different -omics fields: (epi)genomics, transcriptomics, translatomics and proteomics.
Current flagships in portfolio are ribosome profiling, third generation sequencing and single cell omics solutions. With their in-house developed high performant ribosome profiling service, they provide a genome-wide assessment of the mRNA targeted by translating ribosomes. This highly sensitive sequencing-based technology unravels the translatome.
Ribosome footprint profiling can be applied to measure mechanisms in protein synthesis and its regulation in the cell as well as related co-translational processes. It enables quantification of gene-specific translation, discovery of non-canonical translation events, investigation of ribosome elongation speed and pausing, figuring out translation regulation by microRNAs and RNA-binding proteins, determination of mechanisms related to translation initiation and termination. https://www.ohmx.bio
10. Liquid Biopsies, Single-Cell Genomics, Whole Genome Diagnostics (Dr. Gregory Maes, KU Leuven)
11. A zebrafish platform for toxicity assessment and neuroactive drug discovery. (Annelii Ny, Aleksandra Siekierska, Daniëlle Copmans, Michéle Partoens, KU Leuven)
The Laboratory for Molecular Biodiscovery uses a zebrafish platform to safety assessment of compounds (drug candidates, nanoparticles, cosmetics and food) and to perform neuroactive drug discovery with a focus on epilepsy. Visit our interactive demo showcase to discover how our platform can benefit your research needs.
12. An on-chip single B cell mining platform for rapid development of fully human therapeutic antibodies and for immunoprofiling human antibody responses (Dr. Dragana Spasic, Dr. Jolien Breukers, Dr. Maya Imbrechts, KU Leuven)
Monoclonal antibodies are the biggest class of biopharmaceuticals used for the treatment of cancer, autoimmune diseases, inflammatory diseases and several other conditions. The human monoclonal antibody segment is predicted to have the strongest growth in the coming years due to their high effector functions and superior safety, stability and immunogenicity profiles. However, the current human antibody discovery platforms face major challenges (time-consuming, inefficient or unnatural pairing of heavy and light chains). Therefore, PharmAbs and MeBioS developed a microfluidic platform that overcomes these limitations and allows to obtain the natural antibody repertoire, using single B cell screening followed by antibody gene amplification and transient expression in mammalian cells. In our demo, the advantage of our platform will be shortly introduced followed by an overview of the platform’s working mechanism. In the end, the potential applications of our platform will be covered.
13. PLANARIAN STEM CELLS AS A TOOL FOR CARCINOGENIC SCREENING (Jan-Pieter Ploem - Universiteit Hasselt)
The zoology group at the Centre of Environmental Sciences of Hasselt University introduced planarians or flatworms as an alternative model for carcinogenicity testing.
These organisms provide us with the possibility to study stem cells in vivo and their responses can be used in carcinogenic screening methods. This patented method can identify both genotoxic and non-genotoxic carcinogenic compounds.
14. Relab (Remco Baggen - Universiteit Hasselt)
Measuring of functional movements with XSENS system on persons with degenerative joint problems (f.e. arthrosis of the knee). Demonstrations of frequently used exercises such as lunges and steps and direct projection of joint angles on a live screen.
15. Multiple Sclerosis in vitro-to-patient toolbox (dr. An Voets & Prof. dr. Niels Hellings - Universiteit Hasselt)
Building on multidisciplinary teams with decades of experience in the multiple sclerosis field, BIOMED is offering customized services to advance your MS product through consecutive development phases. These services range from in vitro assays to in vivo studies and up to clinical studies with the availability of patient samples collected in a standardized way.